David N Taylor

Summary

Affiliation: VaxInnate Corporation
Country: USA

Publications

  1. doi Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response
    David N Taylor
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, United States
    Vaccine 30:5761-9. 2012
  2. doi Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI)
    David N Taylor
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, USA
    Vaccine 29:4897-902. 2011
  3. pmc Systemic pharmacokinetics of rifaximin in volunteers with shigellosis
    David N Taylor
    Center for Immunization Research, Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Antimicrob Agents Chemother 52:1179-81. 2008
  4. ncbi Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge
    David N Taylor
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Clin Infect Dis 42:1283-8. 2006
  5. pmc Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens
    Andrea J Feller
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Vaccine 29:8487-9. 2011
  6. doi Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate
    Robin McKenzie
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Vaccine 26:3291-6. 2008
  7. ncbi Poorly absorbed antibiotics for the treatment of traveler's diarrhea
    David N Taylor
    Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA
    Clin Infect Dis 41:S564-70. 2005
  8. ncbi Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone
    Herbert L DuPont
    Center for Infectious Diseases, University of Texas School of Public Health, Houston, Texas, USA
    Clin Gastroenterol Hepatol 5:451-6. 2007
  9. ncbi Rifaximin treatment of pathogen-negative travelers' diarrhea
    Herbert L DuPont
    Center for Infectious Diseases, Houston School of Public Health, The University of Texas, Houston, TX, USA
    J Travel Med 14:16-9. 2007
  10. ncbi A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea
    David N Taylor
    Salix Pharmaceuticals, Inc, Morrisville, North Carolina, USA
    Am J Trop Med Hyg 74:1060-6. 2006

Collaborators

Detail Information

Publications11

  1. doi Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response
    David N Taylor
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, United States
    Vaccine 30:5761-9. 2012
    ..HA1 was fused to the C-terminus of flagellin in VAX128A, replaced the D3 domain of flagellin in VAX128B and was fused in both positions in VAX128C...
  2. doi Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI)
    David N Taylor
    VaxInnate Corporation, 3 Cedar Brook Drive, Cranbury, NJ 08512, USA
    Vaccine 29:4897-902. 2011
    ..We evaluated a novel influenza vaccine consisting of the globular head of the HA1 domain of the A/Solomon Islands/3/2006 (H1N1) influenza virus (VAX125) genetically fused to the TLR5 ligand, flagellin, and produced in Escherichia coli...
  3. pmc Systemic pharmacokinetics of rifaximin in volunteers with shigellosis
    David N Taylor
    Center for Immunization Research, Department of International Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Antimicrob Agents Chemother 52:1179-81. 2008
    ..Peak plasma rifaximin concentrations were low after nine consecutive doses, and no accumulation was observed. Rifaximin serum levels were minimal and similar to those previously reported in studies of healthy volunteers...
  4. ncbi Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge
    David N Taylor
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Clin Infect Dis 42:1283-8. 2006
    ..This double-blind, placebo-controlled study was conducted to assess the efficacy of the nonabsorbed oral antibiotic rifaximin to prevent shigellosis in volunteers challenged with Shigella flexneri...
  5. pmc Comparative evaluation of the antibody in lymphocyte supernatant (ALS) and enzyme-linked immunospot (ELISPOT) assays for measuring mucosal immune responses to Shigella antigens
    Andrea J Feller
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
    Vaccine 29:8487-9. 2011
    ..Based on these observations, the ALS assay is a practical and flexible alternative to ELISPOT for measuring mucosal IgA responses to Shigella LPS antigen...
  6. doi Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate
    Robin McKenzie
    Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Vaccine 26:3291-6. 2008
    ..Days of fecal shedding of the vaccine strain, but not dose ingested, correlated with stronger immune responses. These results suggest that to be effective an attenuated Shigella vaccine must colonize well...
  7. ncbi Poorly absorbed antibiotics for the treatment of traveler's diarrhea
    David N Taylor
    Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA
    Clin Infect Dis 41:S564-70. 2005
    ..More research is warranted to delineate the effects of poorly absorbed antibiotics in invasive infection and to assess the potential for the development of bacterial resistance...
  8. ncbi Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone
    Herbert L DuPont
    Center for Infectious Diseases, University of Texas School of Public Health, Houston, Texas, USA
    Clin Gastroenterol Hepatol 5:451-6. 2007
    ..This study evaluated the efficacy and safety of rifaximin-loperamide in the treatment of travelers' diarrhea...
  9. ncbi Rifaximin treatment of pathogen-negative travelers' diarrhea
    Herbert L DuPont
    Center for Infectious Diseases, Houston School of Public Health, The University of Texas, Houston, TX, USA
    J Travel Med 14:16-9. 2007
    ..Antibacterial drugs appear to be effective in shortening the illness of a majority of cases of travelers' diarrhea...
  10. ncbi A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea
    David N Taylor
    Salix Pharmaceuticals, Inc, Morrisville, North Carolina, USA
    Am J Trop Med Hyg 74:1060-6. 2006
    ..35 versus rifaximin). Rifaximin was less effective than ciprofloxacin for invasive intestinal bacterial pathogens. Oral rifaximin is a safe and effective treatment of travelers' diarrhea caused by noninvasive pathogens...
  11. pmc Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers
    David E Katz
    Department of Enteric Infections, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910 7500, USA
    Infect Immun 72:923-30. 2004
    ..Infect. Immun. 67:3437-3443, 1999), have demonstrated that SC602 is a substantially attenuated candidate vaccine that can evoke protection against the most severe symptoms of shigellosis in a stringent human challenge model of disease...